Retatrutide

At a glance

Overview

Developed as LY3437943, retatrutide combines GIP, GLP-1 and glucagon receptor activity in one molecule. Its clinical program evaluates obesity and associated metabolic complications. The 2026 TRIUMPH-1 publication extends the evidence beyond the earlier phase 2 study, including outcomes in participants with knee osteoarthritis or obstructive sleep apnea. These findings come from regulated studies using controlled manufacturing and follow-up. Products sold online under the same name are not the studied product by default. As of this review, the ingredient remains investigational rather than an FDA-approved weight-management medicine.

Supporting sources [1] [2] [3] [4]

How it works

GIP and GLP-1 activity influence glucose-dependent insulin secretion and appetite, while glucagon receptor activity adds effects on hepatic metabolism and energy expenditure. The design balances pathways that do not have identical effects on glucose or food intake. Calling it a triple agonist describes receptor pharmacology; it does not establish that three targets are always safer or clinically superior to two for an individual patient.

Supporting sources [1] [2] [3] [4]

Conditions under investigation

The program studies obesity and associated conditions rather than a nonspecific wellness effect. TRIUMPH-1 included adults with obesity without diabetes and prospectively assessed weight and selected knee-osteoarthritis and sleep-apnea outcomes.

Supporting sources [1]

What the 2026 phase 3 study found

Across 2,339 randomized participants, the highest trial group had a mean 25.0% weight reduction at eighty weeks versus 3.9% with placebo in the treatment-regimen analysis. Pain and sleep-apnea outcomes also improved in relevant subgroups. These are group averages under a specified estimand.

Supporting sources [1]

Observed tolerability and remaining uncertainty

Gastrointestinal adverse events were common. The earlier phase 2 trial also observed dose-related heart-rate increases that peaked and later declined. Larger trials improve confidence but cannot fully characterize rare events or risks after many years of use.

Supporting sources [1] [2]

Why headline percentages can mislead

Phase 2 and phase 3 studies differed in duration, participants and analysis. Comparing their percentages with another drug’s separate trial is not equivalent to a randomized head-to-head comparison. Discontinuation handling also affects reported weight-loss estimates.

Supporting sources [1] [2]

Trial evidence versus approved access

FDA communications identify retatrutide among unapproved products marketed for weight loss. A research-use label, compounded presentation or online certificate does not turn an investigational molecule into an approved medicine or validate a seller’s clinical claims.

Supporting sources [3]

Common questions

Does a positive phase 3 trial mean retatrutide is approved? No. Trial results and regulatory authorization are separate milestones, and the current FDA source identifies it as unapproved.

Can its headline weight loss be directly compared with another medicine's trial? Differences in populations, duration and handling of discontinuation can change estimates; direct comparative studies provide stronger evidence for treatment rankings.

Supporting sources [1] [2] [3]